Altimmune (ALT) Amortization of Deferred Charges (2010 - 2026)
Altimmune (ALT) reported Amortization of Deferred Charges of $218000.0 for Q1 2026, up 13.54% on a QoQ basis from $192000.0 in Q4 2025.
Altimmune (ALT) has 10 years of Amortization of Deferred Charges data on file, last reported at $218000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $218000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $583587.0 (changed N/A YoY) and the FY2025 annual result came in at $363000.0, changed N/A from the prior year.
- Amortization of Deferred Charges rose to $218000.0 in Q1 2026 per ALT's latest filing, from $192000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $218000.0 in Q1 2026 and bottomed at $113000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 218,000.00 |
| Mar 31, 2026 | 218,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Dec 31, 2025 | 192,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Sep 30, 2025 | 113,000.00 |
| Dec 31, 2018 | 60,587.00 |
| Dec 31, 2018 | 60,587.00 |
| Sep 30, 2018 | 120,024.00 |
| Sep 30, 2018 | 120,024.00 |
| Jun 30, 2017 | 59,790.00 |
| Jun 30, 2017 | 59,790.00 |
| Mar 31, 2017 | 38,270.00 |
| Mar 31, 2017 | 38,270.00 |
| Sep 30, 2016 | 1.94 Mn |
| Sep 30, 2016 | 1.94 Mn |
| Jun 30, 2016 | 4,492.00 |
| Jun 30, 2016 | 4,492.00 |
| Mar 31, 2016 | 5,485.00 |
| Mar 31, 2016 | 5,485.00 |
| Dec 31, 2015 | 6,462.00 |
| Dec 31, 2015 | 6,462.00 |
| Sep 30, 2015 | -69,699.00 |
| Sep 30, 2015 | -69,699.00 |
| Jun 30, 2015 | 6,946.00 |
| Jun 30, 2015 | 6,946.00 |
| Mar 31, 2015 | 10,933.00 |
| Mar 31, 2015 | 10,933.00 |
| Dec 31, 2014 | 14,891.00 |
| Dec 31, 2014 | 14,891.00 |
| Sep 30, 2014 | 18,819.00 |
| Sep 30, 2014 | 18,819.00 |
| Jun 30, 2014 | 22,720.00 |
| Jun 30, 2014 | 22,720.00 |
| Mar 31, 2014 | 26,591.00 |
| Mar 31, 2014 | 26,591.00 |
| Dec 31, 2013 | 30,436.00 |
| Dec 31, 2013 | 30,436.00 |
| Sep 30, 2013 | 34,253.00 |
| Sep 30, 2013 | 34,253.00 |
| Jun 30, 2013 | 38,042.00 |
| Jun 30, 2013 | 38,042.00 |
| Mar 31, 2013 | 32,431.00 |
| Mar 31, 2013 | 32,431.00 |
| Dec 31, 2012 | 41,090.00 |
| Dec 31, 2012 | 41,090.00 |
| Sep 30, 2012 | 40,782.00 |
| Sep 30, 2012 | 40,782.00 |
| Dec 31, 2010 | 1.91 Mn |
| Dec 31, 2010 | 1.91 Mn |
| Sep 30, 2010 | 934,655.00 |
| Sep 30, 2010 | 934,655.00 |